Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7112340 | 0.87 | GSK3B (0.45) | KMT2AMAPTMEN1AURKA | |
| SCHEMBL4898620 | 0.87 | ALK (0.61) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL4892691 | 0.86 | ALK (0.55) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL7107687 | 0.83 | ALK (0.57) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL4893816 | 0.81 | SMN1; SMN2 (0.59) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL4894962 | 0.80 | BRAF (0.54) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL7104854 | 0.78 | SMN1; SMN2 (0.56) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL4901287 | 0.77 | RAB9A (0.50) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL4891943 | 0.76 | RAB9A (0.49) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 | |
| SCHEMBL4544847 | 0.72 | MEN1 (0.64) | RAB9AKMT2AKDM4EHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | claimed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | claimed |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | AVENTIS PHARMA S.A. (FR) | 2008-04-17 | — | — | US | disclosed |
| US-7041824-B2 | Purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20060074095-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2006-04-06 | — | — | US | disclosed |
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | AVENTIS PHARMA S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063732-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | RAB9A 3267/4885KMT2A 1869/4885KDM4E 1724/4885 |
| US-20080090849-A1 | NOVEL PURINE DERIVATIVES, PREPARATION METHOD AND USE AS MEDICINES | CDK1, CDK6, PNP | RAB9A 3073/4885KMT2A 1456/4885KDM4E 1381/4885 |
| US-20060074095-A1 | Novel purine derivatives, preparation method and use as medicines | CDK1, CDK6, PNP | RAB9A 3104/4885KMT2A 1673/4885KDM4E 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.